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ABSTRACT
Peripheral Dopamine 2 Receptors Both Modulate Central Dopamine Release
and Adapt Similarly to Central Dopamine 2
Receptors
J. Daniel Obray
Department of Psychology, BYU
Doctor of Philosophy
Alcohol use disorder is a debilitating disorder affecting nearly 5% of people in the United
States. Despite the prevalence of alcohol use disorder few affected individuals seek treatment
and of those who do many will relapse. This highlights a need to develop new treatments for
alcohol use disorder that are both more accessible and more effective. This dissertation
characterizes a novel pathway involved in ethanol enhancement of dopamine levels in the
nucleus accumbens as well as investigating alterations in dopamine 2 receptor expression and
function following an acute dose of ethanol. This was done by using microdialysis to measure
dopamine levels in the nucleus accumbens, single-unit recordings of dopamine neurons in the
ventral tegmental area to measure dopamine neuron activity and place conditioning to measure
the rewarding properties of the intravenous dopamine and ethanol. It was found that activation of
peripheral dopamine 2 receptors by intravenous dopamine enhanced dopamine levels in the
nucleus accumbens and dopamine neuron firing rate in the ventral tegmental area. Additionally,
intravenous dopamine produced a modest conditioned place preference. Domperidone, a
peripheral dopamine 2 receptor antagonist blocked each of these effects. Further, domperidone
blocked ethanol enhancement of dopamine release in the nucleus accumbens and bidirectionally
modulated the sedating effects of ethanol depending on the dose of ethanol administered. The
involvement of peripheral dopamine 2 receptors in ethanol reward could not be ascertained in
these studies as domperidone produced a weak conditioned place aversion. Finally, acute ethanol
was found to enhance dopamine 2 receptor expression in the nucleus accumbens and medial
prefrontal cortex while also enhancing dopamine 2 receptor expression on NK and B cells.
Additionally, ethanol was found to reduce desensitization of dopamine 2 receptors in the ventral
tegmental area. These results demonstrate that activation of peripheral dopamine 2 receptors can
enhance dopamine levels in the nucleus accumbens and that this effect has relevance in
understanding the effects of ethanol on dopamine release in the mesolimbic pathway. These
results also provide evidence for transient upregulation of dopamine 2 receptors in the brain and
on leukocytes suggesting that dopamine 2 receptor levels on leukocytes may be a useful
biomarker for central dopamine function.

Keywords: dopamine 2 receptors, ethanol, microdialysis, leukocytes, ventral tegmental area,
nucleus accumbens, conditioned place preference
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Peripheral Dopamine 2 Receptors Both Modulate Central Dopamine Release and Adapt
Similarly to Central Dopamine 2 Receptors
Alcohol use disorder (AUD) is a debilitating disorder. The prevalence of AUD has
continued to rise in the United States (Grant et al., 2017), with nearly 14.5 million people in the
United States suffering from an AUD in 2017 (Bose et al., 2018). In 2017 individuals with an
AUD accounted for close to 75% of all people with a substance use disorder. Notwithstanding
the negative consequences of AUD, only 15% of individuals with an AUD seek treatment
(Cohen et al., 2007). Further, while treatment for AUD is associated with improved outcomes,
about 40% of individuals receiving treatment for an AUD relapse (Moos & Moos, 2006). The
estimated economic cost of AUD in the United States was an estimated $249 billion in 2010
(Sacks et al., 2015). In addition to the substantial economic effects of excessive drinking, AUD
takes a toll on families. Individuals with AUD are less likely to get married and more likely to
become divorced (Breslau et al., 2011). Despite this, 1 in 10 children in the United States live in
a home where at least one parent has an AUD (Lipari & Van Horn, 2017). These findings
highlight the need to better understand the underlying causes of AUD so that treatment
accessibility and efficacy can be improved.
Current theories related to the genesis and subsequent maintenance of an AUD are based
on a model involving three phases: preoccupation/anticipation, binge/intoxication, and
withdrawal/negative affect (Koob & Le Moal, 2008b; Koob & Volkow, 2010, 2016). As
individuals who use alcohol progress through these phases both the incentive salience of alcohol
paired stimuli (Srey et al., 2015; Villaruel & Chaudhri, 2016) and the reward threshold (Schulteis
et al., 1995; Schulteis & Liu, 2006) are increased, promoting continued, and often increased,
alcohol consumption. This in turn leads the affected individual to progress from a non-dependent
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to a dependent state of alcohol consumption. Two processes stand out among those which have
been proposed to mediate the transition from non-dependence to dependence, the opponent
process theory, and the allostatic model.
The opponent process theory (Solomon, 1980a, 1980b; Solomon & Corbit, 1974) posits
that dependence results from a strengthened b-process (anti-hedonic process). This strengthened
b-process is the result of repeated activation of the b-process to restore homeostatic equilibrium
following an imbalance induced by activation of the a-process (hedonic process) following
alcohol consumption. Ultimately, the strengthening of the b-process results in a state of
dysphoria as the b-process overcompensates for the repeated activation of the a-process. This
alcohol induced state of dysphoria, then, is most readily alleviated by further stimulation of the
a-process by continued alcohol consumption, although this approach yields diminishing returns
over time as the b-process continues to be strengthened in response to activation of the a process.
The allostatic model (Ahmed & Koob, 2005; Koob, 2003; Koob & Le Moal, 2001,
2008a; Koob & Schulkin, 2019) postulates that dependence results from an altered homeostatic
setpoint. Effectively, it is believed that repeated stimulation of the reward pathways inside the
brain results in cellular and molecular changes which increase the reward threshold.
Additionally, activation of these reward pathways leads to activation of, and cellular and
molecular changes within, the antireward pathways in the brain. These changes create an
enhanced stress response which, when combined with an increased reward threshold, produces a
dysphoric state. Once again, this state of dysphoria can be alleviated by alcohol consumption,
however, this risks further adaptation within both the reward and antireward pathways.
A key point of agreement between the opponent process theory and the allostatic model is
that alcohol consumption is initially maintained by the positive reinforcing effects of alcohol,
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recently referred to as the “light side of addiction”. This in turn progresses to negative
reinforcement-maintained alcohol consumption as repeated activation of the positive reinforcing
response leads to compensatory mechanisms (the b-process or cellular and molecular changes,
sometimes referred to as the “dark side of addiction”) which create a state of dysphoria that
persists in the absence of alcohol. This progression is easily mapped onto the three-phase model
of AUD with the positive reinforcing effects of alcohol falling under the binge/intoxication
phase, while the negative reinforcing effects of alcohol fall under the preoccupation/anticipation,
and withdrawal/negative affect stages.
In order to understand the relevance of D2Rs to addiction it is important to consider that
one commonality among nearly all substance abuse disorders is a reduction in striatal D2R
expression in individuals with a history of substance abuse (Volkow et al., 1996, 2001; Wiers et
al., 2017). This reduction has been linked with relapse (Jadhav et al., 2018), and craving (Heinz
et al., 2004, 2005; Zijlstra et al., 2008). As these reductions in D2R expression are consistent
across many different substance use disorders it is believed that D2Rs are one of the targets
which adapt in response in response to repeated use of substances of abuse.
The allostatic model of AUD posits that dependence emerges as the result of cellular and
molecular changes following exposure to ethanol. As striatal D2Rs are consistently shown to be
downregulated in humans with a history of AUD (Volkow et al., 1996, 2007), striatal D2Rs may
adapt to chronic ethanol exposure in such a way as to induce dependence. This adaptation may
then be reflective of an allostatic state. Studies performed in Wistar rats show that chronic
ethanol exposure reduces D2R expression although the reduction may not be apparent until after
the Wistar rats no longer have access to ethanol (Feltmann et al., 2018; Hietala et al., 1990;
Jadhav et al., 2018; Rommelspacher et al., 1992; Syvälahti et al., 1988). Despite many studies
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examining D2R expression following chronic ethanol consumption, adaptations in D2R
expression following acute ethanol consumption are far less common. Given the relevance of
altered D2R expression to the ethanol dependent state in AUD it is important to improve
understanding of how acute ethanol effects striatal D2R expression.
In studying the binge/intoxication phase and the “light side” of addiction it is important to
understand the mesolimbic dopaminergic pathway and how alcohol is thought to affect this
pathway. The mesolimbic pathway originates in the ventral tegmental area (VTA) and terminates
in the NAc. This pathway is commonly referred to as the reward pathway. This moniker is
primarily the result of two sets of observation. First, DA neurons in the VTA display an
increased firing rate in response to an unexpected reward while displaying decreasing firing in
the absence of an expected reward (Ljungberg et al., 1991, 1992; Schultz et al., 1992, 1993).
This phenomenon has been termed reward prediction error (Hollerman & Schultz, 1998; Schultz,
1998; Schultz et al., 1998) and has been construed to constitute the neural underpinning of the
Rescorla-Wagner model of associative learning. Second, natural reinforcers such as sex (Pfaus et
al., 1990), food (Radhakishun et al., 1988), and water (Young et al., 1992) all enhance DA levels
in the NAc. Further, nearly all drugs of abuse also enhance DA levels in the NAc (Di Chiara &
Imperato, 1988). These parallel findings have led to the conclusion that the mesolimbic
dopaminergic pathway is responsible for processing reward and that dopamine release in the
nucleus accumbens is a scalar index of reward (Wise, 2004).
While the importance of the mesolimbic pathway to reward processing seems apparent, a
careful survey of the literature related to DA neuron activity in the VTA and DA release in the
NAc reveals a more complex relationship between mesolimbic dopaminergic activity and reward
than that presented above. To illustrate this complexity, consider the following findings. First,
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while DA levels in the nucleus accumbens are enhanced by natural reinforcers and drugs of
abuse (Di Chiara & Imperato, 1988), DA levels in the nucleus accumbens are also enhanced by
footshock (Young, 2004) and tail pinch (Budygin et al., 2012), both of which are generally
considered to be aversive stimuli. Further, footshock and tail pinch increase the firing rate of
VTA DA neurons (Guarraci & Kapp, 1999; Zweifel et al., 2011) while footshock and restraint
increase the number of spontaneously active VTA DA neurons (Valenti et al., 2011). Finally,
reducing the activation of VTA DA neurons during aversive conditioning blocks the acquisition
of the conditioned response (Zweifel et al., 2011).
When considering what these findings mean for the conceptualization of enhanced VTA
DA neuron firing and NAc DA levels as a scalar index of reward it becomes apparent that this
conceptualization is woefully incomplete. While rewarding stimuli enhance the firing rate of
VTA DA neurons as well as DA levels in the NAc it is apparent that these effects do not only
signal reward. As such, it must be considered that VTA DA neurons may not be homogenous,
and that some neurons may encode reward while others encode aversion, or alternatively, that
VTA DA neurons encode some other aspect of the associative learning process such as
perceptual saliency, attention, or “surprise.” While the studies I report herein do not endeavor to
explore the nuances of the relationship between mesolimbic DA transmission and reward, these
complexities are mentioned in passing here as the dogma in the field of addiction research is that
drugs of abuse are rewarding because they enhance DA neuron firing rate in the VTA and DA
levels in the NAc. The studies I report are discussed in terms of the DA hypothesis of reward as
it is the current prevailing dogma within the field of addiction research. As such, it was important
to discuss the caveats that exist when interpreting increased dopaminergic neurotransmission
within the mesolimbic pathway as being synonymous with reward.
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Ethanol is thought to enhance DA release within the mesolimbic pathway by enhancing
VTA DA neuron firing rate and NAc DA levels (see Figure 1). These effects are believed to be
direct effects as ethanol applied to VTA DA neurons ex vivo enhances the firing rate of said
neurons (Brodie et al., 1990). Additionally, rats will self-administer ethanol into the VTA, an
action which enhances DA release in the NAc (Ding et al., 2009; Rodd-Henricks et al., 2000;
Rodd et al., 2004). These findings, however, ignore the inability of direct application of ethanol
to enhances VTA DA neuron firing rate at physiologically relevant doses ex vivo (Brodie et al.,
1990). The EC50 for ethanol enhancement of VTA DA neuron firing rate ex vivo is more than 20
times that of the ED50 in vivo (Brodie et al., 1990; Gessa et al., 1985). Moreover, the EC50 for ex
vivo experiments is sufficiently large that if administered in vivo it would cause the rat to pass
out. These discrepancies strongly suggest that ethanol effects on VTA DA neurons are not direct
effects at physiologically relevant doses and thus that they cannot be readily studied ex vivo. One
possible explanation for this is that the increased sensitivity of VTA DA neurons to ethanol in
vivo is due to a neuroimmune modulation of VTA DA neuron firing resulting from altered
inflammatory profiles following ethanol consumption. A putative pathway that could be involved
in this response is laid out and explored in the studies I relay hereafter.
Figure 1
Model Showing the Mesolimbic Pathway in Ethanol Use
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Note. The model shows the mesolimbic pathway in both a naïve and ethanol intoxicated state as per the
prevailing dogma in AUD research. In the intoxicated state ethanol enhances DA release in the NAc and
decreases GABA activity in the VTA relative to the naïve state.

The studies I report here were focused primarily on the effects of a putative pathway
involving peripheral D2Rs on the mesolimbic dopaminergic system. Specifically, I showed that
such a pathway enhanced DA levels in the nucleus accumbens (NAc) and the firing rates of DA
neurons in the VTA. In addition, I supported the likelihood of the pathway by demonstrating its
role in conditioned place preference and negative affect. These findings were then extended to
ethanol use where I demonstrated that such a pathway was involved in the ability of ethanol to
enhance DA levels in the NAc. I further supported the involvement of this pathway in ethanol
effects by demonstrating its role in modulating ethanol induced sedation. Finally, I characterized
changes in D2R expression both in the brain and on circulating leukocytes in the periphery
following an acute dose of ethanol.
For the study outlined in Chapter 2 the hypotheses were as follow: First, peripheral D2Rs
mediate the ability of intravenous (IV) DA to enhance DA release in the NAc; Second, IV DA
will enhance the firing rate of VTA DA neurons; Third, IV DA will be reinforcing; Fourth, IV
DA will enhance locomotor activity.
For the study outlined in Chapter 3 the hypotheses were as follow: First, ethanol will
enhance plasma DA levels; Second, peripheral D2Rs will mediate enhancement of DA levels in
the NAc following ethanol administration; Third, ethanol effects on evoked DA release in the
NAc will not involve D2Rs; Fourth, antagonism of peripheral D2Rs will attenuate reductions in
locomotor activity following ethanol administration.
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For the study outlined in Chapter 4 the hypotheses were as follow: First, ethanol will
transiently increase D2R expression on neurons; Second, ethanol will increase D2R expression
on circulating leukocytes; Third, ethanol will reduce D2R desensitization.
These studies were carried out with the purpose of characterizing a putative pathway that
could explain the discrepancy between the doses of ethanol required to enhance the firing rate of
VTA DA neurons in vivo and ex vivo. This was done to identify potential targets for treating
AUD. Additionally, these studies included a component to assess D2R expression in the brain
and on circulating leukocytes following an acute dose of ethanol. This was done to determine
whether acute ethanol evinces similar alterations in central and peripheral D2R expression. If
D2R expression in the brain and on circulating leukocytes adapted in a similar manner this
would be important as it would allow for the use of a less costly and more readily accessible
procedure to assess central dopaminergic function in recovering addicts. This would allow
clinicians and patients to use this technique to help measure recovery as indexed by D2R
expression whereas currently positron emission tomography is too costly a technique to allow for
widespread use to measure D2R expression and use it as an index of recovery.
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Chapter 1
Dopamine is a cell-signaling molecule. In the brain, DA plays a key role in processes
such as motor coordination (Avila-Luna et al., 2018; Emerich et al., 1993), locomotor activity
(Gatica et al., 2020; Iversen, 1970), perceptual saliency (Cieślak & Rodriguez Parkitna, 2019;
McCutcheon et al., 2019), affective state (Brudzynski et al., 2012; Mulvihill & Brudzynski,
2019; Scardochio et al., 2015), and reinforcement learning (Dabney et al., 2020; Lak et al., 2020;
Schultz et al., 1993). In addition to being synthesized within the major dopaminergic pathways,
DA is also synthesized outside the brain. Peripheral DA comes from a number of sources
including the gastrointestinal tract (Eisenhofer et al., 1997), the sympathetic ganglia (Kokubun et
al., 2019; Libet & Tosaka, 1970), the adrenal medulla (Shepherd & West, 1953), and leukocytes
(Cosentino et al., 2002; Gopinath et al., 2019; Josefsson et al., 1996; Laukova et al., 2013). In the
periphery, DA is involved in processes such as the regulation of gut motility (Auteri et al., 2016;
Schuurkes & Van Nueten, 1984), renal function (McDonald et al., 1964; Meyer et al., 1967),
blood pressure (Russell, 2019), and adaptive immunity (Ambrosi et al., 2017; Kawano et al.,
2018).
Dopamine does not readily cross the blood brain barrier (BBB) although following
intranasal and, to a lesser degree, IV administration, DA may enter neurons of the olfactory tract
(Dahlin et al., 2000, 2001) likely via DA transporters expressed in the nasal mucosa (Chemuturi
et al., 2006). Intranasal DA can enhance DA release in the nucleus accumbens (NAc) (de Souza
Silva et al., 2008), modulate locomotor activity (Buddenberg et al., 2008; de Souza Silva et al.,
2016), and enhance performance in memory tasks (Trossbach et al., 2014; Wang et al., 2017).
Additionally, intranasal DA decreases hyperexcitability and improves attention in the Naples
High Excitability rat model of attention deficit hyperactivity disorder (Ruocco et al., 2009, 2014)
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and decreases rat vocalizations related to a negative emotional state during restraint (Talbot et
al., 2017). These behavioral results are consistent with an effect of intranasal DA on central
dopaminergic functioning.
Dysregulation of central dopaminergic pathways has been closely linked to a number of
mental disorders including Parkinson’s disease (Bokobza et al., 1984), attention deficit
hyperactivity disorder (Volkow et al., 2009), schizophrenia (Lodge & Grace, 2007; PurvesTyson et al., 2017), restless legs syndrome (Lanza et al., 2017), and drug addiction (Nader et al.,
2006). In each of these conditions, in addition to the changes in central dopaminergic function,
there have been changes in peripheral dopaminergic markers on immune cells (Ersche et al.,
2011; Ilani, 2001; Kustrimovic et al., 2016; Mitchell et al., 2018). Additionally, a lack of D2R
expression on CD4+ T cells is protective against neurodegeneration of DA neurons in an animal
model useful for the study of Parkinson’s disease (González et al., 2013). These findings indicate
an interaction between dopaminergic function in the central nervous system and in the immune
system. This is consistent with increasing evidence indicating that DA plays a key role in
mediating neuroimmune interactions (Levite, 2016).
I designed the present study to investigate the effects of peripheral D2R activation on DA
neurotransmission within the mesolimbic pathway. I administered IV DA in the presence of
domperidone (DOM), a peripheral D2R antagonist (Clemens-Hemmelmann et al., 2016;
Heykants et al., 1981; Laduron & Leysen, 1979), while collecting dialysate samples from the
NAc. Previous experimenters had provided indirect evidence that peripherally administered DA
enhanced DA levels in the NAc by enhancing neuronal DA release. In this study, I tested the
relation directly by recording from putative DA neurons in the ventral tegmental area (VTA)
immediately before and after IV DA administration and by determining if enhanced DA levels in
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the NAc following IV DA administration were action-potential dependent. Finally, I evaluated
IV DA for its potential reinforcing properties using a place-conditioning paradigm. I also
hypothesized that peripherally administered DA would, at least in part, enhance DA levels
through a peripheral D2R-dependent mechanism and that enhanced extracellular DA levels in the
NAc by peripherally administered DA would be neuronally mediated. The purpose of this study
was to provide evidence for a putative pathway involving peripheral D2Rs that could enhance
DA levels in the NAc and DA neuron firing rate in the VTA. Additionally, behavioral evidence
was sought to support a role of this pathway in reward-related behavior with the end goal of
testing for involvement of this proposed pathway in the effects of ethanol on the mesolimbic
pathway. In order to do this it was first necessary to provide evidence that the pathway exists,
and that this pathway indeed involved peripheral D2Rs and was not the result of DA crossing the
BBB.
Materials and Methods
Animal Subjects
Male Wistar rats weighing more than 300 g from a breeding colony at Brigham Young
University (BYU) were the subjects in the studies reported here. All rats were socially housed in
a temperature- and humidity-controlled environment. They were given ad libitum access to food
and water. The lighting in the room where subjects were housed was maintained on a 12-hr
on/12-hr off reverse light/dark schedule for the duration of the experiments. All procedures were
approved by the Institutional Animal Care and Use Committee at Brigham Young University and
carried out in accordance with NIH guidelines.
Drugs and Chemicals
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Dopamine hydrochloride (H8502, Sigma-Aldrich, Saint Louis, MO), eticlopride
hydrochloride (E101, Sigma-Aldrich), quinpirole hydrochloride (1061, Tocris Bioscience,
Bristol, UK), and phentolamine hydrochloride (P7547, Sigma Aldrich) were all prepared prior to
each injection by solubilizing in 0.9% sodium chloride. Domperidone (J63681, Alfa Aesar,
Haverhill, MA) was mixed in a solution of 0.02% acetic acid and gently heated until fully
dissolved. Heparin sodium (American Pharmaceutical Partners, Inc, Schaumberg, IL) was
diluted to 10 units per ml in 0.9% sodium chloride. Gentamicin sulfate (VetOne, Boise, ID) was
diluted to 5 mg/ml in 0.9% sodium chloride. The injection volume for each of these drugs was 1
ml/kg. All drugs were administered IV. Urethane (44804-30, Alfa Aesar) was dissolved at a
concentration of 150 mg/ml in 0.9% sodium chloride.
Surgical Procedure
For IV drug administration, rats were implanted with a catheter in the jugular vein. The
catheter was passed subcutaneously to exit the back of the rat through an infusion guide cannula
(313-000BM-10-5UP/SPC, Plastics One, Roanoke, VA). At the end of the surgery, the wound
was irrigated with gentamicin sulfate. After implantation, patency was maintained by a daily
flush of heparinized saline. For microdialysis, a guide cannula (MD-2250, Bioanalytical Systems
Incorporated [BASI], West Lafayette, IN) was implanted under stereotaxic control in the NAc at
the following coordinates from bregma: +1.7 mm anteroposterior (AP), +0.8 mm mediolateral
(ML), and -6.0 mm dorsoventral (DV). All subjects were anesthetized for the duration of the
surgical procedure using isoflurane (1.5% - 2.0%). Subjects were given one week to recover
post-surgery and received post-operative care, including: buprenorphine (0.5 – 1.0 mg/kg, IP)
twice daily for two days post-surgery and carprofen (2 mg; Bio-Serv, Flemington, NJ) in an
edible tablet once a day for one-week post-surgery.
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Microdialysis and Liquid Chromatography
On each test day, microdialysis probes (MD-2200, BASI) were inserted into the NAc
through the guide cannula. Artificial cerebral spinal fluid (aCSF) containing 148 mM sodium
chloride, 2.7 mM potassium chloride, 1.2 mM calcium chloride, and 0.85 mM magnesium
chloride was perfused through the probe at a rate of 2.0 µl/min. To test for neuronal release of
DA, a modified aCSF was used. The modified aCSF was prepared as described above with the
following alterations: calcium chloride was excluded from the solution, and 37 mM lidocaine
was added. During a baseline period, samples were collected and analyzed every 20 min until a
stable baseline was established. This baseline period lasted for a minimum of 2 hr. After
obtaining a stable baseline DA signal, DOM (1 mg/kg iv), phentolamine (PHENT; 1 mg/kg iv),
or vehicle (VEH; 1 ml/kg iv) was injected 10 min prior to injection with either DA (0.1 – 3.0
mg/kg iv), or VEH (1 ml/kg iv). Dialysate samples were then collected and analyzed for an
additional 2 hr.
Determination of the DA content in the dialysate was performed using a highperformance liquid chromatography (HPLC) pump (Ultimate 3000, Dionex) connected to a
coulometric detector (Coulochem III, ESA). The coulometric detector included a guard cell
(5020, ESA) set at +275 mV, a screen electrode (5014B, ESA) set at -100 mV, and a detection
electrode (5014B, ESA) set at +220 mV. DA was separated using a C18 reverse phase column
(HR-80, Thermo Fisher Scientific, Waltham, MA). Mobile phase containing 90 mM sodium
phosphate monobasic, 50 mM citric acid, 1.7 mM 1-octanesulfonic acid, 50 µM
ethylenediaminetetraacetic acid, 10% vol/vol acetonitrile, and 0.3% vol/vol triethylamine was
pumped through the system at a flow rate of 0.5 ml/min. Dopamine levels following drug
administration were expressed as a percentage of the baseline DA levels. Baseline DA levels
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were computed as the average DA concentration of a minimum of 3 consecutive stable
collections occurring prior to drug administration.
Recording of VTA DA Neuron Spikes
Prior to extracellular recording of VTA DA neuron spikes rats were first anesthetized
using urethane (1.2 g/kg ip). An IV catheter was then implanted, and the rat was placed in a
stereotaxic instrument, and a micropipette electrode was inserted into the VTA (from bregma: 5.3 to -5.7 mm AP, +0.6 to +1.0 mm ML, and -7.8 to -9.2 mm AP) using an Inchworm 8200
microdrive (EXFO Burleigh). Body temperature was maintained at 37.4 ± 0.2 ºC for the duration
of the surgery using a feedback-regulated heating pad. Once a suitable neuron had been
identified, its baseline firing rate activity was recorded for a minimum of 5 min after which
PHENT (1 mg/kg iv), DOM (1 mg/kg iv), or VEH (1 ml/kg iv) were administered and the firing
rate of the neuron was recorded for an additional five min. At that point, DA (3 mg/kg iv) was
administered and the neuron was recorded for another 20 min at which point quinpirole (QUIN;
0.1 mg/kg iv) was administered. The firing rate was averaged during the baseline period, during
the period immediately following the administration of IV DA in which the firing rate of the
neuron was inhibited, and during the period following the inhibition of the neuron when the
neuron was excited. In addition to the mean firing rate, the durations of the period of inhibition
and of the subsequent period of excitation were recorded. On trials where there was no obvious
effect following drug administration, the magnitude of the inhibition and excitation were
calculated by using the average firing rate for a period of time equal to the average duration of
the inhibition and excitation respectively across all trials in which there was an effect. It was then
used in the analysis and expressed as a percentage of the baseline firing rate. The durations of the
periods of inhibition and excitation were expressed in seconds.
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Extracellular potentials were recorded by 3.0 M potassium chloride filled micropipettes
(4-10 MΩ). Potentials were amplified using a Multiclamp 700A amplifier (Molecular Devices,
LLC, San Jose, CA). Single-unit activity was filtered at 300 Hz to 10 KHz for “filtered”
recordings and filtered at 0.1 Hz to 10 KHz for “unfiltered” recordings and displayed on a digital
oscilloscope (TDS 2002, Tektronix, Beaverton, OR). Potentials were sampled at 20 kHz with
National Instruments (Austin, TX) data acquisition boards in Macintosh computers (Apple,
Cupertino, CA). Action potentials were discriminated using a WP-121 spike discriminator
(World Precision Instruments [WPI], Sarasota, FL). Discriminated spikes were captured by a
National Instruments NB-MIO-16 digital I/O and counter timer acquisition board and processed
with National Instruments LabVIEW customized virtual instrument software.
Ventral tegmental area DA neurons were identified using previously established criteria
(Ungless & Grace, 2012). These criteria included: a relatively slow firing rate (1-12 Hz), a
biphasic positive-negative action potential, a start to trough action potential duration of equal to
or greater than 1.1 ms during “filtered” recordings (Ungless et al., 2004), and strong inhibition of
firing rate by systemic administration of QUIN (0.1 mg/kg).
Place Conditioning and Locomotor Activity
The place-conditioning apparatus consisted of a 32 in x 16 in x 16 in plexiglass chamber
subdivided into two 16 in x 16 in x 16 in compartments by a guillotine door. The apparatus was
housed inside a sound- attenuating box. The two compartments were distinguished by a rough
acrylic floor inside one compartment and a smooth plexiglass floor inside the other. Both floors
were suspended 1 in above the base of the apparatus. A piezoelectric sensor was mounted in the
center of the floor. The signal from the piezoelectric transducer was amplified (10x) and filtered
(0.1 - 50 Hz) using a CyberAmp 820 amplifier (Molecular Devices). This signal was then
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digitized at 100 samples/s using a National Instruments board on a PXI-1011 chassis connected
to a Windows-PC (Microsoft, Redmond, WA). Recorded piezoelectric signals were then
analyzed for locomotor activity by calculating the root mean square using Igor Pro 7
(Wavemetrics, Inc, Lake Oswego, OR). Additionally, piezoelectric signals were analyzed using
custom software to determine how much time the rat spent in each compartment.
Classical conditioning occurred in a place-conditioning paradigm consisting of three
phases: pretest, conditioning, and posttest. In the pretest phase, the guillotine door was removed,
and the rats were allowed 30 min to explore the apparatus. Locomotor activity in each
compartment was recorded for individual rats. In condition 1 there were four groups (n = 10) in
which the conditioning phase consisted of four experimental trials during which the guillotine
door was in place, and either IV DA (0.1 or 3.0 mg/kg iv), DOM (1.0 mg/kg iv), or VEH (1.0
ml/kg iv) was administered in (paired with) the less-preferred chamber and 4 control trials during
which VEH (1.0 ml/kg iv) was paired with the more-preferred chamber. Each trial lasted for 10
min, and each rat received two trials per day on four consecutive days. A control trial was
presented during the morning and an experimental trial during the evening on each day. Both the
control and experimental trials occurred during the light phase. Pairing of the US (IV DA) and
the CS (less preferred compartment) occurred by backward conditioning. The UR was enhanced
NAc DA levels and increased VTA DA neuron firing rate. The CR was presumed to also be
enhanced NAc DA levels and increased VTA DA neuron firing rate as the conditioning of
enhanced NAc DA levels to a CS has been previously demonstrated (de Souza Silva et al.,
2016). Additionally, in Condition 2, two additional groups of rats received conditioning trials
identical to those of the first group except that the injection of IV DA was immediately preceded
by an injection of DOM (1.0 mg/kg iv). Locomotor activity was recorded during each
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conditioning trial. Finally, the posttest phase was identical to the pretest phase and occurred on
the day after the final conditioning trial. Compartment preference was again established on the
basis of locomotor activity.
Ultrasonic Vocalizations
Ultrasonic vocalizations were recorded during each conditioning trial for each rat.
Recordings were performed using a miniMIC ultrasonic microphone (Binary Acoustic
Technology, Tucson, AZ) attached to a Windows-PC (Microsoft) running SCAN’R software
(Binary Acoustic Technology). The recorded files were then analyzed for ultrasonic
vocalizations using DeepSqueak (Coffey et al., 2019).
Statistical Analysis
Statistical analyses were performed using Stata 15.1 (StataCorp LLC, College Station,
TX). All data were assessed for normality, and outliers were identified prior to analysis. The
Shapiro-Wilks test was used to test for normality, and the interquartile range rule was used to test
for outliers. Any datum identified as an outlier was bounded by the relevant limit for analysis
purposes after checking for data-input errors. Roughly 7% of all datapoints were classified as
outliers using this method. The remaining data were analyzed using analysis of variance
(ANOVA). Between-subjects factors included: dose (of DA), drug (pretreatment condition), and
aCSF (modified or normal). Time was treated as a within-subjects factor. A Greenhouse-Geisser
correction for sphericity was applied to the analyses of within-subjects factors. Post-hoc
comparisons were corrected for multiple comparisons using the Bonferroni correction. All values
reported here are the mean ± SEM. All confidence intervals are 95%. For the statistical analysis,
p < 0.05 was considered significant.
Results
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Experiment 1A: The Effects of IV DA on DA Levels in the NAc
To determine the effects of IV DA on DA levels in the NAc, rats received IV injections
of DA at the following doses: 0.1 mg/kg (n = 8), 0.5 mg/kg (n = 8), 1.0 mg/kg (n = 18), and 3.0
mg/kg (n = 20), as well as a VEH injection (n = 6). Analysis of the data revealed that IV DA
enhanced DA levels in the NAc in a dose-dependent manner (dose: F(4,55) = 3.57, p = 0.01,
partial η2 = .21, CI [0.01, 0.34]; see Figure 2B). DA levels in the NAc were found to vary over
time which was reflective of the ability of IV DA to enhance DA release in the NAc at only
some, but not all, timepoints (time: F(6, 296) = 7.65, p = 0.01, partial η2 = 0.13, CI [0.06, 0.19]).
Finally, the increase in DA levels produced by IV DA administration varied over time (dose x
time: F(24, 296) = 3.88, p = 0.01, partial η2 = 0.24, CI [0.10, 0.26]). To better identify the
interaction between time and dosage level, post-hoc comparisons were performed and revealed
that significant increases in DA levels in the NAc only occurred at doses of 1.0 mg/kg DA (F(6,
296)

= 6.05, p < 0.01) and 3.0 mg/kg DA (F(6, 296) = 30.23, p < 0.01), and not at 0.1 mg/kg DA (F(6,

296)

= 0.04, p = 1.00) or 0.5 mg/kg DA (F(6, 296) = 0.05, p = 1.00). Further, DA levels in the NAc

were only significantly different among groups during the first 20 min following the injection
(F(4, 55) = 29.96, p < 0.01).
To determine whether the increase in DA levels in the NAc following IV DA was due to
action-potential-dependent release, 11 rats received two injections of DA (1.0 mg/kg iv)
separated by a minimum of 5 hr. These injections occurred under urethane anesthesia. one while
standard aCSF was being perfused through the probe and the other while modified aCSF (zero
calcium and lidocaine) was being perfused. The time between the two injections was sufficient
for a stable baseline to be achieved prior to the second injection. The order of the injection
conditions was counterbalanced to account for order effects. Analysis of the data revealed that
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IV DA) enhancement of NAc DA levels was blocked by modified aCSF (F(1, 10) = 9.46, p = 0.01,
partial η2 = 0.49, CI [0.03, 0.71]; see Figure 2C). Further, enhancement of DA levels in the NAc
when standard aCSF was being perfused varied over time (aCSF x time: F(3, 60) = 3.25, p = 0.05,
partial η2 = 0.14, CI [0.00, 0.27]). There was no main effect of time (F(3, 60) = 2.35, p = 0.10).
These results suggest that IV DA enhancement of DA levels in the NAc was due to actionpotential-dependent DA release. As compared with the previous experiment in which IV DA was
administered in freely moving animals it was apparent that urethane blunted the magnitude of the
increase in NAc DA levels produced by IV DA and also that the duration of the increase was
somewhat prolonged.
Figure 2
Dose-Dependent Dopamine Levels in the Nucleus Accumbens Following Intravenous Dopamine Injection

-50

[DA] (% Baseline)

0

B

DA

10 nA

*

12 SEC

Baseline
0-20 Min DA (1.0 mg/kg, IV)

-100

DA

**

VEH
DA (0.1 mg/kg, IV)
DA (0.5 mg/kg, IV)
DA (1.0 mg/kg, IV)
DA (3.0 mg/kg, IV)

2

1000

8
6

**

4
2

100

8
6

0

2

4
6
Time in Min

C

220

8

DA

200
[DA] (% Baseline)

nA

50

DA

100

HVA

DOPAC

A

10

0

20

40

Modified aCSF + DA (1.0 mg/kg, IV)
aCSF + DA (1.0 mg/kg, IV)

180
160
140
120

*

100

*

*

80
0

20

40
Time in Min

60

60
80
Time in Min

100

120

PERIPHERAL DOPAMINE RECEPTORS

20

Note. Data are means ± SEM. (A) Representative chromatogram of dialysate analyzed by HPLC before
and after IV DA (1.0 mg/kg). The trace from the final baseline sample is superimposed in red on the trace
from the sample following the first infusion of IV DA. The inset in the top right corner is a magnified view
of the DA peaks from the two samples indicated by the asterisk. Dopamine metabolites DOPAC and HVA
are also readily apparent in the trace. (B) The time courses of the dosage-dependent DA levels in the
NAc (C) To determine whether IV DA enhanced DA levels in the NAc through an action potentialdependent mechanism, IV DA (1.0 mg/kg) was administered twice in the same rat. One administration
occurred while the probe was being perfused with standard aCSF and the other while the probe was
being perfused with modified aCSF.

Experiment 1B: The Effects of the Blockade of Peripheral Dopamine 2 Receptors on
Dopamine Levels in the Nucleus Accumbens
To determine whether peripheral DA or α-adrenergic receptors mediate IV DA-induced
NAc DA release, rats were pretreated with the peripheral D2R antagonist DOM (1 mg/kg iv; n =
15), the α-adrenergic receptor antagonist PHENT (1 mg/kg iv; n = 14), or VEH (1 ml/kg iv; n =
18) 5 min prior to the administration of IV DA (1 mg/kg). Analysis of the data revealed that the
enhancement of NAc DA levels produced by IV DA was dependent on the pretreatment
condition (F(2, 44) = 3.36, p = 0.04, partial η2 = 0.13, CI [0.00, 0.30]; see Figure 3A). Levels also
varied over time (time: F(6, 199) = 17.38, p < 0.01, partial η2 = 0.34, CI [0.22, 0.42]). Finally, the
decrements in IV DA-enhancement of DA levels in the NAc caused by pretreatment with
PHENT or DOM varied over time (drug x time: F(12, 199) = 3.75, p = 0.01, partial η2 = 0.18, CI
[0.05, 0.23]). Post-hoc analyses indicated that DA levels in the NAc were significantly increased
by IV DA administration following VEH (F(6, 199) = 23.43, p < 0.01) and PHENT (F(6, 199) = 5.45,
p < 0.01) pretreatment, but were not significantly increased following DOM pretreatment (F(6,
199)

= 0.46, p = 0.84). Further, DA levels in the NAc only differed among treatment groups

between 0 and 20 min post-injection with IV DA (F(2, 44) = 28.56, p < 0.01). In this interval, the
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decrement produced by PHENT in IV DA-mediated DA levels in the NAc was greater than that
produced by VEH (F(1, 44) = 11.85, p < 0.01). DOM pretreatment produced an even larger
decrement (F(2, 44) = 13.43, p < 0.01).
To assess whether PHENT or DOM affected DA levels in the NAc, as well as to provide
evidence for the inability of DOM to cross the BBB, rats were administered DOM (1 mg/kg iv; n
= 6), PHENT (1 mg/kg iv; n = 6), the centrally-active D2R antagonist eticlopride (ETIC; 1
mg/kg iv; n = 8), or VEH (1 ml/kg iv; n = 6), and microdialysis was performed as previously
described. There were drug dependent differences in DA levels in the NAc (F(3, 22) = 6.01, p <
0.00, partial η2 = 0.45, CI [0.07, 0.60]; see Figure 3B), but they were not time dependent (drug x
time: F(18, 132) = 2.07, p = 0.06). Dopamine levels in the NAc did not vary significantly with time
(F(6, 132) = 2.23, p = 0.10). In post hoc comparisons, only rats treated with ETIC showed changes
in NAc DA levels, namely, increases in DA levels (F(1, 22) = 51.33, p < 0.01). This finding
indicated that none of the drugs that has been used to pretreat rats prior to the administration of
IV DA altered DA levels in the NAc on their own. Nor did DOM cross the BBB, as DA levels
were enhanced only by the centrally active ETIC.
Figure 3
Peripheral Dopamine 2 Receptor Antagonists Block Enhancement of Nucleus Accumbens Dopamine
Levels by Intravenous Dopamine

PERIPHERAL DOPAMINE RECEPTORS

1400

DA

B
VEH + DA (1.0 mg/kg, IV)
PHENT + DA (1.0 mg/kg, IV)
DOM + DA (1.0 mg/kg, IV)

1200

[DA] (% Baseline)

[DA] (% Baseline)

A

22

1000

**

800
600
400

**

200
0

20

INJECTION
240

VEH
PHENT
DOM
ETIC

*

200

**

**

**

160
120
80

40

60
80
Time in Min

100

120

0

20

40

60
80
Time in Min

100

120

Note. Values are means ± SEM. (A) Effects over time of intravenous administration of DA (1 mg/kg) on
DA levels in the NAc in the presence of vehicle (VEH; n=18), phentolamine (PHENT; n=14), a peripheral
α-adrenergic receptor antagonist, and domperidone (DOM; n=15), a peripheral D2R antagonist. (B)
Effects over time of VEH (1 ml/kg iv; n=6), DOM (1 mg/kg iv; n=6), PHENT (1 mg/kg iv; n=6), or on NAc
DA levels on their own. ETIC (1 mg/kg iv; n=8) on DA levels in the NAc.

Experiment 1C: The Effects of IV DA on Putative VTA DA Neuron Firing Rate
In order to determine the effect of IV DA on putative VTA DA neuron firing rate, rats
were administered IV DA (3.0 mg/kg) 5 min after an injection of VEH (n = 7), PHENT (n = 7),
or DOM (n = 7). A clear, biphasic effect on the firing rate of putative DA neurons in the VTA
was observed (see Figure 4A). This effect was characterized by transient inhibition that began
almost immediately after administration of IV DA and lasted for an average of 90.34 s. It was
followed almost immediately by an excitation that lasted for an average of 326.04 s. The baseline
firing rate of the putative DA neurons was not significantly affected by the pretreatment
condition (F(2, 18) = 1.64, p = 0.22; see Figure 4B). The pretreatment condition also did not
change the magnitude of the inhibition produced by IV DA (F(2, 18) = 0.48, p = 0.63; see Figure
4C). However, the extent of the excitation produced by IV DA was affected by the pretreatment
condition (F(2, 18) = 4.41, p = 0.03, partial η2 = 0.33, CI [0.00, 0.54]; see Figure 4D). This effect
was found to be mainly due to the antagonistic effect of DOM on the excitation of putative DA
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neurons in the VTA (F(1, 18) = 8.78, p = 0.02). PHENT did not significantly alter the excitation of
putative DA neurons (F(1, 18) = 1.67, p = 0.42).
These results are consistent with the previous finding that DOM eliminated the
enhancement of DA levels in the NAc by IV DA administration. The finding that PHENT
attenuated the enhancement of DA levels in the NAc following IV DA administration but did not
alter the excitation of putative VTA DA neurons following IV DA was puzzling. I performed an
exploratory analysis using a t-test to compare the duration of excitation produced by IV DA
infusion between the VEH and PHENT pretreatment groups. I found that PHENT pretreatment
did not significantly decrease the duration of the excitation produced by IV DA (t(12) = 1.70, p =
0.06, Hedges’s g = 0.85, CI [-0.21, 1.87], one-tailed, where the duration of excitation produced
by VEH was 441.30 ± 117.88 sand that produced by PHENT was 232.43 ± 36.69 s). This result
supports the conclusion that IV DA enhancement of DA levels in the NAc involves neuronal
release of DA. The question remains of how such enhancement is achieved.
Figure 4
The Effect of IV DA on the Firing Rate of Putative Dopamine Neurons in the VTA
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group. (A) Representative trace of the firing rate of a putative DA neuron in an experiment in which IV DA
was administered. Note the transient inhibition of firing rate immediately after the injection (point C) and
the subsequent excitation (point D). (B) The firing rate of putative DA neurons during pretreatment. (C)
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Experiment 1D. Place Preference Conditioned by IV DA
To determine whether IV DA would produce CPP, following a baseline pretest session,
two sets of four groups of rats received classical-conditioning trials during four successive pairs
of 10-min trials (see Figure 5A). There were 10 rats in each group. For the first set,
conditioning involved administration of either VEH (1 ml/kg iv), DOM (1 mg/kg iv), or IV DA
(0.1 or 3.0 mg/kg iv)
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In the pretest, there was no statistical difference among the groups in their initial
preference for one of the two compartments over the other (drug dose: F(2, 54) = 1.31, p = 0.28;
drug type: F(1, 54) = 0.00, p = 0.98; dose x drug: F(2, 54) = 0.17, p = 0.85). According to the
analysis of the difference scores for the pretest and posttest sessions [posttest time spent in the
compartment where administration occurred (s/min) - pretest time in the same compartment
(s/min)], rats in the first group that were treated with IV DA increased the time they spent in the
compartment where it had been administered (drug dose: F(2, 54) = 3.27, p = 0.05, partial η2 =
0.11, CI [0.00, 0.26]; see Figure 5B). This constituted a reversal of their initial preference.
However, the size of the reversal was attenuated by pretreatment with DOM in the second group
(F(1, 54) = 4.67, p = 0.04, partial η2 = 0.08, CI [0.00, 0.24]). There was no significant interaction
between treatment with DOM and the dosage level of IV DA (F(2, 54) = 1.83, p = 0.17). Thus, IV
DA effects on peripheral D2Rs may be considered rewarding.
Analysis of the locomotor activity between the pretest and posttest sessions revealed no
significant effect of drug dose, drug type, or session on locomotor activity (see Figure 5C). As
previously stated, the results indicated that the use of IV DA produced a marked decrease in
locomotor activity during conditioning (F(2, 53) = 8.88, p < 0.01, partial η2 = 0.25, CI [0.06, 0.41];
see Figure 5D), and this reversal of original preference was attenuated by pretreatment with
DOM (F(1, 53) = 4.15, p = 0.05, partial η2 = 0.07, CI [0.00, 0.23]). Further, there was no
significant interaction between the dosage level of IV DA and the DOM dose on locomotor
activity during conditioning trials (F(2, 53) = 1.15, p = 0.32). These results provide strong evidence
the CPP that was dependent on the activation of peripheral D2Rs.
Figure 5
The Effects of Intravenous Dopamine on Conditioned Place Preference
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presented in half of the trials and IV DA in the other half. VEH trials were presented during the morning
and IV DA trials during the evening. (B) The amount of time spent in the compartment where
administration occurred increased (compared to the pretest) in the IV DA (0.1 mg/kg) and IV DA (3.0
mg/kg) groups in Condition 1. This effect was attenuated by pretreatment with DOM (1 mg/kg iv) in
Condition 2 (C) Locomotor activity during the pretest and posttest sessions. (D) Locomotor activity in the
compartment in which treatment occurred as a percentage of the activity level in the VEH group.

Experiment 1E: Effects of Intravenous Dopamine on Ultrasonic Vocalizations
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Affective state as a function of IV DA was measured using USVs during conditioning
trials. Calls were classified as indicating a negative affective state [18 kHz - 32 kHz (Kagawa et
al., 2017; Knutson et al., 2002)] or a positive affective state [32 kHz – 96 kHz (Knutson et al.,
2002; Scardochio et al., 2015)]. Treatment with DOM significantly increased negative affect
during conditioning trials in both Condition 1 and Condition 2 (drug: F(2, 44) = 97.61, p = 0.03,
partial η2 = 0.12, CI [0.00, 0.30]; see Figure 6A), including the trials with 3.0 mg/kg IV DA
following DOM pretreatment (F(1, 44) = 4.98, p = 0.03). The increase in negative affect was not
IV DA dose-dependent (dose x drug: F(2, 44) = 0.73, p = 0.49). There also was not a significant
effect of the dose of IV DA on negative affect associated USVs (dose: F(2, 44) = 0.03, p = 0.97).
There was not a significant effect of dose (F(2, 44) = 2.51, p = 0.09; see Figure 6B), DOM (F(1, 44)
= 0.46, p = 0.50) or of any combination of the two on positive affect (F(2, 44) = 1.02, p = 0.37).
Thus, the activation of peripheral D2Rs by IV DA appears to reduce negative affect as measured
by USV.
Figure 6
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Discussion
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This study highlighted a putative novel pathway involving peripheral D2Rs that modulate
DA neuron firing in the VTA as well as DA release in the NAc. Activation of this pathway by IV
DA produced reduced negative affect as measured by USVs and reversed place preferences as
measured by locomotion. These and other findings from the experimental series could have
relevance for the interplay between the immune system and the central nervous system in DArelated disorders.
Experiment 1A
The finding of dose-dependent increases in NAc DA levels following IV DA injection is
consistent with the results of earlier studies demonstrating that intranasal DA enhances DA
levels in the NAc (de Souza Silva et al., 2008). I demonstrated that the increase is firing ratedependent and mediated by both peripheral D2Rs and α-adrenergic receptors. Two dosage levels
of IV DA (1.0 and 3.0 mg/kg) produced DA levels in the NAc over 100-fold greater than those
observed at baseline. These effects are on the scale comparable to those seen following
administration of drugs of abuse, such as amphetamine (Di Chiara & Imperato, 1988). Though
the time course of enhancements in NAc DA release in this study differed from the time course
reported previously following intranasal DA administration, the differences were likely the result
of different routes of administration as well as differences between the anesthetization procedure
used in the previous study and the non-anesthetized procedure I used.
Experiment 1B
There are multiple means by which peripheral D2Rs and α-adrenergic receptors could
modulate central DA levels. For exsmple, activation of D2R and α-adrenergic receptors on
leukocytes mediate neuroimmune interactions that may modulate dopaminergic signaling in the
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mesolimbic pathway. Also, changes in blood pressure and vascular perfusion resulting from IV
DA administration may alter DA activity within the mesolimbic circuit.
Stimulation of D2Rs on naive CD8+ T cells triggers increased binding to ICAM-1 and
fibronectin as a result of integrin activation (Watanabe et al., 2006), which promotes increased
extravasation, with DA also encouraging migration of naïve CD8+ T cells (Watanabe et al.,
2006). In addition to encouraging extravasation and homing of CD8+ T cells, activation of D2Rs
also drives increased transcription and secretion of TNFα and IL-10 by resting T cells (Besser et
al., 2005). IL-10, in turn, can enhance DA neuron firing and DA levels in the NAc (unpublished
data). Additionally, activation of α-adrenergic receptors on monocytes increases IL-1β secretion
in response to a challenge with LPS (Grisanti et al., 2011). It is currently unknown, however,
whether α-adrenergic receptor activation on monocytes is sufficient to enhance IL-1β secretion
on its own, or whether IL-1β has the ability to alter DA dynamics within the mesolimbic circuit.
IV DA administration modulates both blood pressure and cerebral blood flow in a dosedependent manner (Brodde, 1982; Oudart et al., 1981; von Essen et al., 1980). At high doses, an
increase in blood pressure, accompanied by a decrease in cerebral blood flow, would be expected
(von Essen et al., 1980). However, this effect would be blocked by administration of an αadrenergic receptor antagonist, such as PHENT or DOM. One potential side effect of IV DA
infusions performed without PHENT or DOM pretreatment is ischemia (Chen & O’Shea, 1998;
Russell, 2019). Cerebral ischemia is known to produce dramatic increases in central DA levels
(Chang et al., 1993; Yoshimoto et al., 2014). It is possible that the increases in NAc DA levels
resulting from IV DA were caused, in part, by the induction of cerebral ischemia. Both DOM
and PHENT could have relieved cerebral ischemia by antagonizing α-adrenergic receptors
responsible for vasoconstriction. DOM was more effective than PHENT in reducing DA levels in
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the NAc following IV DA. DOM and PHENT do not differ significantly in their potency or
affinity for the α-adrenergic receptor (Ennis & Cox, 1980), suggesting that the greater efficacy of
DOM in this experiment was due to its antagonism of the D2Rs in addition to that of αadrenergic receptors.
Experiment 1C
Consistent with the findings that IV DA enhances DA levels in the NAc through an
action potential-dependent mechanism, IV DA also produced an increase in DA neuron firing
rate in the VTA. This effect was blocked by DOM but not PHENT. This outcome was consistent
with DOM’s antagonism of DA levels in the NAc produced by IV DA. But it was inconsistent
with PHENT’s attenuation of the effect. It may be that IV DA-mediated increases in NAc DA
levels are the direct product of increases in DA cell firing but that peripheral α-adrenergic
receptors have an indirect effect on NAc DA terminals (Yorgason et al., 2017).
Experiments 1D and 1E
In Experiment 1D, I demonstrated that IV DA administration resulted in CPP. In
Experiment 1E, I showed that IV DA reduced negative affect (see Talbot et al., 2017). In contrast
to previous studies that showed increased locomotor activity in response to intranasal DA (de
Souza Silva et al., 2008) or no effect (Buddenberg et al., 2008), I found that IV DA decreased
locomotor activity and thereby produced a reversal of baseline position preference.
Conclusions
Intravenous DA enhanced DA levels in the NAc in a dose-dependent manner. It did so by
enhancing the firing rate of putative DA neurons in the VTA and by enhancing action potentialdependent release of DA in the NAc. The effects were partially blocked by the α-adrenergic
antagonist PHENT, suggesting that they were mediated in part by increases in blood pressure.
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These increases may be related to cerebral ischemia triggered by vasoconstriction. DOM, which
is a peripheral D2R and α-adrenergic antagonist, produced a larger decrement in the
enhancement of DA levels in the NAc and DA neuron firing in the VTA than PHENT did. This
result reflected the involvement of peripheral D2R receptors, possibly through a neuroimmune
interaction. I also showed that IV DA produced CPP involving locomotor activity and reduced
negative affect in the form of USVs. These effects were both attenuated by DOM. Together, the
findings demonstrated the possibility that a novel pathway involving activation of peripheral
D2Rs modulates dopaminergic function in the mesolimbic circuit. These findings are relevant to
DA-related mental disorders and to potential treatments thereof.
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Chapter 2
Alcohol use disorder is a debilitating condition with severe health, social, and economic
effects for affected individuals (Rehm, 2011). As with many drugs of abuse, ethanol enhances
DA levels in the NAc (Di Chiara & Imperato, 1985; Feduccia et al., 2014; Imperato & Di Chiara,
1986). Ethanol does so by enhancing the firing rate of DA neurons in the VTA (Gessa et al.,
1985; Vandegrift et al., 2017). The effects of ethanol on the mesolimbic dopaminergic pathway
have been linked to the rewarding properties of ethanol (Bahi & Dreyer, 2012, 2014; Heidbreder
et al., 2007; Pina & Cunningham, 2014; Young et al., 2014), although they do not fully account
for the rewarding effects of ethanol (Rassnick et al., 1993).
Although ethanol enhances the firing rate of DA neurons in the VTA, there is a clear
disparity between its effects in vivo, where ethanol enhances DA neuron firing rate with an ED50
of 4.25 mM (Gessa et al., 1985) and ex vivo, where it enhances DA neuron firing rate with an
EC50 of 98.4 mM (Brodie et al., 1990). That is, although ethanol has a direct effect on VTA DA
neurons (Ding et al., 2009, 2011), it has indirect effects as well. One possible explanation for the
disparity in enhanced DA neuron firing rates in vivo and ex vivo is that some of the effects of
ethanol on DA neurons are mediated by a neuroimmune interaction involving peripheral immune
cells.
In Chapter 2, I demonstrated that activation of peripheral D2Rs and α-adrenergic
receptors by IV DA can enhance DA levels in the NAc and DA neuron firing rate in the VTA. I
posited that this effect may be the result of a neuroimmune interaction mediated by activation of
D2Rs and α-adrenergic receptors. Ethanol is known to increase sympathetic tone (da Silva et al.,
2013; Eisenhofer et al., 1983; Kovács et al., 2002; Spaak et al., 2008) and to alter cytokine levels
(Airapetov et al., 2019; Patel et al., 2019; Roberts et al., 2019). As such, I designed a new
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experiment to determine whether ethanol enhancement of DA levels in the NAc involves
activation of peripheral D2Rs, and whether peripheral D2Rs are involved in the rewarding
properties of ethanol. Specifically, I administered ethanol in the presence of DOM while
collecting dialysate samples from the NAc. Additionally, I did so in a CPP procedure. I
anticipated that DOM would reduce the enhancement of NAc DA levels by ethanol and that
ethanol-mediated reward would be concomitantly attenuated.
Materials and Methods
Animal Subjects
Male Wistar rats weighing more than 260 g from a breeding colony at Brigham Young
University were used for these studies. All rats were socially housed and given ad libitum access
to food and water. The lighting in the room where the subjects were housed was maintained on a
12-hr on/12-hr off light/dark cycle and the temperature and humidity were controlled. All
experimental procedures were approved by the Institutional Animal Care and Use Committee at
BYU, Daegu Haany University, and the Korea Institute of Toxicology and carried out in
accordance with NIH guidelines.
Drugs and Chemicals
Dopamine hydrochloride (Sigma-Aldrich), (-)-eticlopride hydrochloride (Sigma-Aldrich)
and phentolamine hydrochloride (Sigma-Aldrich) were prepared fresh just prior to each injection
by dissolution in a solution of 0.9% sodium chloride. Domperidone (Alfa Aesar) was mixed in a
solution of 0.02% acetic acid and gently heated until fully dissolved. Each of these drugs was
injected at a volume of 1 ml/kg. Ethanol was diluted to 16% wt/vol using 0.9% sodium chloride.
Surgical Procedure
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Subjects were implanted with a guide cannula (BASI) in the NAc at the following
coordinates from bregma: +1.7 mm AP, +0.8 mm ML, and -6.0 mm DV. Subjects were
anesthetized for the duration of the procedure using isoflurane (1.5% - 2.0%) and were allowed
one-week post-surgery for recovery. Post-operative care consisted of buprenorphine (0.01 - 0.05
mg/kg, IP) bis in die for 48 hours and daily carprofen (2 mg; Bio-Serv, Flemington, NJ) in an
edible tablet for one-week post-surgery.
Microdialysis and High-Performance Liquid Chromatography
On the test day, microdialysis probes (BASI) extending 2 mm beyond the end of the
guide cannula were inserted into the NAc. Artificial cerebral spinal fluid was perfused through
the probe at a rate of 2.0 µl/min. During the baseline period microdialysis samples were collected
and analyzed every 20 min until a stable baseline was established. Then VEH (1 mg/ml ip) or
DOM (1 mg/kg ip) was injected 10 min prior to administration of ethanol (0.5 – 4.0 g/kg ip).
Dialysate samples were collected and analyzed every 20 min for an additional 3 hr.
Determination of the DA content in the dialysate was performed using a HPLC pump
(Ultimate 3000, Dionex) connected to a coulometric detector (Coulochem III, ESA). The
coulometric detector included a guard cell (5020, ESA) set at +275 mV, a screen electrode
(5014B, ESA) set at -100 mV, and a detection electrode (5014B, ESA) set at +220 mV. DA was
separated using a C18 reverse phase column (HR-80, Thermo Fisher Scientific). Mobile phase
was pumped through the system at a flow rate of 0.5 ml/min. Dopamine levels following drug
administration were expressed as a percentage of the baseline DA levels, which were computed
as the average DA concentration of a minimum of three consecutive stable collections occurring
during baseline prior to drug administration.
Fast Scan Cyclic Voltammetry
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Electrically evoked DA release in the NAc was measured by fast scan cyclic voltammetry
(FSCV) in isoflurane anesthetized rats (1.5% - 2.0%). Using a stereotaxic, a bipolar stainless
steel Formvar-coated stimulating electrode was inserted into the medial forebrain bundle (MFB;
from bregma: -2.5 mm AP, +1.9 mm ML, and -8.0 to -8.2 mm DV) and a carbon fiber electrode
was inserted into the NAc (from bregma: +1.6 mm AP, +1.9 mm ML, and -6.5 to -7.2 mm DV).
The MFB underwent biphasic electrical stimulation (4 ms pulses, 60 pulse, 500 µA, 60 Hz) at 2
min intervals. DA levels were monitored until five consecutive stable collections had occurred.
Once the signal had stabilized, VEH (1 ml/kg ip), DOM (1 mg/kg ip), or ETIC (1 mg/kg ip) was
administered followed by ethanol (2.0 g/kg ip) 10 min later. Collection then continued for an
additional 30 min. In a separate set of experiments, DOM (1 mg/kg ip) was administered after a
stable baseline was attained and then ETIC (1 mg/kg ip) was administered 1 hr following the
administration of DOM. Collections continued for an additional hr following ETIC
administration.
Baseline DA release was calculated using the final three collections during the baseline
period. The baseline was updated following the first drug-injection period (VEH or DOM) using
the final three collections during that period. As ETIC enhanced phasic DA release, on trials
where ETIC administration preceded ethanol administration, the stimulating current was reduced
sufficiently to return the DA signal to its baseline level prior to the administration of ethanol.
The effects of the first drug injection on DA release were expressed as a percentage of the
baseline from the baseline period. The effects of the second drug injection on DA release were
expressed as a percentage of the updated baseline computed following the first drug injection.
Data were analyzed for drug effects using the average of the final three collections for each drug
injected. Recordings were performed and analyzed using custom LabVIEW-based (National
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Instruments, Austin, TX) software (Yorgason et al., 2011). All other equipment and recording
parameters were as described previously (Jang et al., 2017).
Measurement of Plasma Catecholamines
To determine the effect of ethanol on plasma catecholamine levels, subjects were
anesthetized using isoflurane (1.5% - 2.0%) and implanted with an IV catheter in the jugular
vein. Subjects were then placed in a stereotaxic, and a microdialysis probe was inserted into the
NAc (from bregma: +1.7 mm AP, +0.8 mm ML, and -8.0 mm DV). Microdialysis was
performed as described above with the only difference being that the rat was now anesthetized.
Blood (800 µl/sample) was drawn via the IV catheter with fluid replacement (heparinized
ringer’s solution) 5 min prior to injection with ethanol as well as 10, 20, 30, 60, 120, and 180
min following the administration of ethanol. These samples were processed as previously
described (Yang et al., 2002) and analyzed using the HPLC system described earlier. The mobile
phase consisted of 97 mM sodium phosphate monobasic, 31 mM sodium phosphate dibasic, 2.8
mM 1-octanesulfonic acid, 171 µM ethylenediaminetetraacetic acid, and 12% vol/vol methanol.
The flow rate was 0.5 ml/min.
Ethanol Place Conditioning
The place-conditioning paradigm (PCP) apparatus consisted of a 32 in x 16 in x 16 in
plexiglass chamber subdivided into two 16 in x 16 in x 16 in compartments by a guillotine door.
The apparatus was housed inside a sound-attenuating box. The two compartments were
distinguished by a rough acrylic floor inside one compartment and a smooth plexiglass floor
inside the other. Both floors were suspended 1 in above the base of the apparatus. A piezoelectric
sensor was mounted in the center of each the floor. The signal from the piezoelectric transducer
was amplified (10x) and filtered (0.1 – 50 Hz) using a CyberAmp 820 amplifier (Molecular
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Devices, LLC). This signal was then digitized at 100 Hz using a National Instruments board on a
PXI-1011 chassis connected to a Windows-PC (Microsoft). Piezoelectric signals were analyzed
using custom software to determine how much time each rat spent in each chamber. I had earlier
found this apparatus to be biased for Wistar rats as Wistar rats displayed an initial preference for
the smooth-floored compartment.
The PCP consisted of four phases: habituation, pretest, conditioning, and posttest. In the
habituation phase, the door was removed, and rats were placed individually in the apparatus for
20 min on a single day. The pretest phase consisted of two additional trials identical to that in the
habituation phase, each on a separate but consecutive day. Initial position preference was
established on the basis of the average time spent in each chamber. The conditioning phase
consisted of six daily trials in each of four conditions. In Condition 1, VEH (1 ml/kg ip) was
used in the nonpreferred chamber in each trial. In conditions 2-4, the agent used was DOM (1
mg/kg ip), VEH + Ethanol (1.0 g/kg ip), and DOM + Ethanol (1.0 g/kg ip), respectively. The six
conditioning trials were followed by another set of six in which the only VEH was used. Thus,
there was a total of 12 conditioned trials. The trial type was alternated every other day. In
conditions involving ethanol, the ethanol injections were given 10 min before the subjects were
placed in the apparatus. The DOM or VEH injections were given 10 min before the ethanol
injections. The posttest phase consisted of one trial lasting 40 min on the day after the final
conditioning trial. A CPP score (posttest time on the originally nonpreferred floor [s/min] pretest time on the same floor was computed for each rat.)
Locomotor Activity
Locomotor activity was measured in the same apparatus used for place conditioning. All
animals were tested in the chamber with the smooth floor while the guillotine door was in place.
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Piezoelectric signals were analyzed for locomotor activity by calculating the root mean square
using Igor Pro 7 (Wavemetrics, Inc., Lake Oswego, OR). Locomotion trials lasted for 30 min.
All subjects received injections of VEH (1 mg/ml ip), DOM (1 mg/kg ip), and ETIC (1 mg/kg ip)
followed by injections of either VEH or ethanol (0.5 - 4.0 g/kg ip) for a total of 20 trials per
subject. The order of the injections was randomized, with a minimum of two days between
injections.
Statistical Analysis
Statistical analyses were performed using Stata 15.1 (StataCorp LLC). All data were
assessed for normality and for outliers. Normality was assessed using the Shapiro-Wilks test,
while outliers were identified using the IQR method. Any datum identified as an outlier was
checked for data-input error and, if no data-input error had occurred, fenced to the relevant outer
limit for outlier detection. Roughly 5% of all data points were classified as outliers using this
criterion. All data were analyzed using ANOVA or t-tests. Between-subject factors included
ethanol dosage level and post-trial drug (VEH or ethanol). Within-subjects factors included:
time, dose (locomotor activity only), and drug (locomotor activity only). All analyses included
all relevant factors. A Greenhouse-Geisser correction for sphericity was applied to the results for
within-subjects factors. Post-hoc comparisons were analyzed using the Bonferroni correction. All
data reported below were means ± SEM. All confidence intervals were 95% and significance
was assessed at p < 0.05.
Results
Experiment 2A
To determine the effects of an acute dose of ethanol on plasma DA levels, ethanol was
administered to rats at four doses: 0.5 g/kg (n = 6), 1.0 g/kg (n = 6), 2.0 g/kg (n = 6), and 4.0
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g/kg (n = 6). Dopamine levels from three collections in the first 30-min post-injection interval
were averaged and analyzed. This analysis revealed a dose-dependent effect (F(3, 20) = 3.17, p =
0.05, partial η2 = 0.32, CI [0.00, 0.51]; see Figure 7A). Plasma DA levels were positively
correlated with plasma norepinephrine (NE) levels, suggesting that the increase in plasma DA
may have resulted from sympathetic spillover (release of neurotransmitter from sympathetic
nerve endings; r2 = 0.38, p < 0.01; see Figure 7B). Finally, there was no significant correlation
between plasma DA levels and DA levels in the NAc following ethanol administration (p = 0.08;
see Figure 7C).
Figure 7
Ethanol Dosage and Plasma DA Level
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relationship between plasma DA and plasma NE levels. C) Plasma DA levels and NAc DA levels following
ethanol administration.

Experiment 2B
To determine the effects of ethanol on DA release in the NAc using microdialysis, rats
were administered VEH (n = 6) or ethanol at the following doses: 0.5 g/kg (n = 11), 1.0 g/kg (n =
13), 2.0 g/kg (n = 28), and 4.0 g/kg (n = 17). Figure 8A shows that ethanol enhanced DA levels
in the NAc in a dose-dependent manner (F(4, 70) = 2.88, p = 0.03, partial η2 = 0.14, CI [0.00, 0.25]
over time (F(9, 569) = 6.02, p < 0.01, partial η2 = 0.09, CI [0.04, 0.12]). The duration and timing of
the increase in DA levels in the NAc was also dose dependent (dose x time: F(36, 569) = 3.16, p <
0.01, partial η2 = 0.17, CI [0.07, 0.17]). These results confirmed that ethanol enhanced DA levels
in the NAc as measured by microdialysis.
To determine the effects of ethanol on evoked phasic DA release in the NAc, rats were
injected with ethanol (2 g/kg ip; n = 27). It did not significantly decrease evoked phasic DA
release in the NAc (t(26) = 1.63, p = 0.06; one-tailed paired t-test; see Figure 8B).
Figure 8
Ethanol and Mesolimbic DA
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Experiment 2C
To determine whether peripheral D2Rs are involved in ethanol-induced enhancement of
DA release in the NAc, rats were injected with ethanol in the presence of DOM at the following
doses of ethanol: 0.5 g/kg (n = 10), 1.0 g/kg (n = 8), 2.0 g/kg (n = 8), and 4.0 g/kg (n = 8). These
data were then compared to data obtained previously (Experiment 2A) when ethanol was
injected in the presence of VEH. Ethanol enhanced DA levels in the NAc, and the duration of the
effect was dose dependent (F(27, 790) = 1.74, p = 0.03, partial η2 = 0.06, CI [0.00, 0.06]; see
Figures 9A - 9D). The same figures show that DOM attenuated the effect of ethanol on DA
levels in the NAc in a manner that was similarly dose- and time-dependent (F(9, 790) = 2.53, p =
0.02, partial η2 = 0.03, CI [0.00, 0.04]. The three-way interaction between drug type,dosage
level, and length of effect was also significant (F(27, 790) = 2.21, p < 0.01, partial η2 = 0.07, CI
[0.01, 0.07]).
To determine whether any of the drugs affected NAc DA levels directly, and to provide
evidence that DOM did not cross the BBB, rats were injected with VEH (1 ml/kg ip, n = 6),
DOM (1 mg/kg ip; n = 7), or ETIC (1 mg/kg ip; n = 6). Analysis of the data indicated that the
treatment condition significantly affected DA levels in the NAc (drug: F(2, 16) = 4.77, p = 0.02,
partial η2 = 0.37, CI [0.00, 0.58]; see Figure 9E). Post-hoc analysis indicated that only ETIC
enhanced DA levels in the NAc (F(9, 16) = 3.27, p < 0.02). These results provide evidence that
DOM did not cross the BBB during these experiments.
Figure 9
Effects of Ethanol on DA Levels in the NAc

PERIPHERAL DOPAMINE RECEPTORS
Ethanol 0.5 g/kg

160

B

Ethanol
DOM + Ethanol

140
120
100
80

40

0

80
120
Time in Min

160

*

140
120
100

160

0

Ethanol 2.0 g/kg

160

D

Ethanol
DOM + Ethanol

140

*

120

40

100
80

80
120
Time in Min

160

Ethanol 4.0 g/kg

180
160

[DA] (% Baseline)

[DA] (% Baseline)

Ethanol
DOM + Ethanol

80

60

C

Ethanol 1.0 g/kg

200
180

[DA] (% Baseline)

[DA] (% Baseline)

A

42

Ethanol
DOM + Ethanol

140
120
100
80

60

60
40

80
120
Time in Min

E

200

[DA] (% Baseline)

0

160

160

0

40

80
120
Time in Min

160

VEH
DOM
ETIC

180
140

**

120

**

100
80
60
40
0

40

80
120
Time in Min

160

Note. Data are means ± SEM. (A-D) Ethanol dose and DA levels in the NAc (E) Effects of VEH, DOM,
and Eticlopride (ETIC) on DA levels in the NAc.

To provide further evidence that DOM does not cross the BBB, I recorded evoked phasic
DA release in five rats both in the presence of DOM, a peripherally active D2R antagonist,or
ETIC, a centrally active D2R antagonist. Eticlopride significantly enhanced evoked phasic DA
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release in the NAc, as compared to DOM (t(4) = -2.38, p = 0.04; one-tailed paired t-test; see
Figures 10A and 10C). These results are consistent with the failure of DOM to cross the BBB.
To determine whether peripheral D2Rs were involved in ethanol’s to reduction of evoked
phasic release in the NAc, I injected rats with ethanol (2.0 g/kg ip) in the presence of VEH (1
ml/kg ip; n = 27), DOM (1.0 mg/kg ip; n = 9) or ETIC (1.0 mg/kg ip; n = 9). Ethanol decreased
evoked phasic DA release in the NAc (F(1, 42) = 4.83, p = 0.03, partial η2 = 0.10, CI [0.00, 0.29];
see Figures 10B and 10D) regardless of the preceding injection (F(2, 42) = 0.04, p = 0.96. Nor was
there an interaction (F(2, 42) = 0.19, p = 0.83). These results indicate that the effects of ethanol on
evoked phasic DA release in the NAc occurred independently of peripheral or central D2Rs.
Figure 10
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Note. Data are means ± SEM. (A) An averaged trace for evoked phasic DA release in the NAc following
administration of DOM (1 mg/kg ip) and ETIC (1 mg/kg ip). (B) Averaged trace for evoked phasic DA
release following pretreatment with VEH (1 ml/kg ip), DOM (1 mg/kg ip), or ETIC (1 mg/kg ip). (C)
Domperidone- and ETIC-enhanced evoked phasic DA release. (D) Ethanol’s effects on evoked phasic DA
release following pretreatment with VEH, DOM, or ETIC. “Base” refers to baseline and “Rebase” to the reestablishment of baseline.

Experiment 2D
To determine whether activation of peripheral D2Rs was involved in alcohol-mediated
CPP, VEH (1 ml/kg ip; n = 25), DOM (1 mg/kg ip; n = 16), VEH + ethanol (1.0 g/kg ip; n = 25),
or DOM + ethanol (1.0 g/kg ip; n = 10) was injected prior to each rat’s placement in the lesspreferred chamber. Ethanol produced a preference reversal (F(1, 72) = 7.28, p = 0.01, partial η2 =
0.09, CI [0.01, 0.23]; see Figure 11). Pretreatment with DOM attenuated the effect of ethanol
(F(1, 72) = 3.87, p = 0.05, partial η2 = 0.05, CI [0.00, 0.17]). Preference scores (Δ s/min) were
calculated as the difference between the posttest time on the ethanol paired floor and the pretest
time on the ethanol paired floor.
Figure 11
Effects of Pretreatment Conditions on CPP
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Note. Values are means ± SEM. CPP scores are shown as a function of pretreatment in four groups of
rats.

Experiment 2E
To determine whether peripheral D2Rs affected the frequency of locomotion, I injected
18 rats with VEH (1 ml/kg ip), DOM (1 mg/kg ip), or ETIC (1 mg/kg ip) followed by injections
of VEH or ethanol (0.5 - 4.0 g/kg ip). Ethanol decreased locomotor activity in a dose-dependent
manner (dose: F(4, 204) = 59.44, p < 0.01, partial η2 = 0.54, CI [0.44, 0.60]; see Figure 12A). The
pretreatment condition also altered locomotor activity (drug: F(2, 34) = 27.67, p < 0.01, partial η2 =
0.62, CI [0.24, 0.67]) and did so in a manner that was dependent on the subsequent ethanol
dosage (F(8, 204) = 7.36, p < 0.01, partial η2 = 0.22, CI [0.10, 0.29]). Post-hoc analysis revealed
that ETIC suppressed locomotor activity when paired with VEH (t(17) = 3.35, p = 0.01) and with
the ethanol dosages of 0.5 g/kg (t(17) = 5.03, p < 0.01), and 1.0 g/kg (t(17) = 3.65s, p < 0.01).
DOM reduced locomotor activity when the ethanol dose was 0.5 g/kg ip (t(17) = 2.80, p = 0.02).
Both DOM (t(17) = -5.69, p < 0.01) and ETIC (t(17) = -4.04, p < 0.01) enhanced locomotor activity
when the ethanol dose was 2.0 g/kg ip.
To further explore the role of peripheral D2Rs on ethanol induced sedation rats were
assessed for their latency to right following an injection of ethanol (4.0 g/kg ip) preceded by
either VEH (1 mg/kg ip; n = 16) or DOM (1 mg/kg ip; n = 16). Analysis revealed that DOM did
not reduce the latency to right (t(30) = 1.90, p = 0.07; see Figure 12B). This suggests that
peripheral D2Rs are not involved in ethanol induced loss of righting reflex.
Figure 12
Effects of Ethanol Dosage on Locomotor Activity Following Pretreatment with VEH, ETIC, or DOM
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Discussion
This series of experiments extended previous work on a potential, novel pathway for
modulating DA levels in the NAc. Specifically, it demonstrated the role of activation of
peripheral D2Rs in the effects of acute ethanol in rats. Blockade of peripheral D2Rs prior to
administration of ethanol attenuated ethanol-induced increases in DA levels in the NAc but did
not alter the effects of ethanol on evoked phasic DA release. Antagonism of peripheral D2Rs by
DOM affected CPP in a manner that could be considered aversive.
Experiment 2A
The finding that ethanol produced rapid enhancement of plasma DA levels is consistent
with previous findings demonstrating enhanced sympathetic tone following ethanol
administration (da Silva et al., 2013; Eisenhofer et al., 1983; Kovács et al., 2002; Spaak et al.,
2008). Moreover, increased plasma DA levels were y correlated with increased plasma NE
levels, suggesting that increased plasma DA was the result of increased sympathetic overflow.
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Experiment 2B-2C
In Experiment 1, I demonstrated that IV DA enhanced DA levels in the NAc through a
peripheral D2R-dependent pathway and a peripheral α-adrenergic receptor-dependent pathway.
The effect of IV DA on VTA DA neurons was blocked by antagonism of peripheral D2Rs but
not by antagonism of peripheral α-adrenergic receptors. I therefore postulated that peripheral
D2R activation enhances DA levels in the NAc by enhancing DA neuron firing rate. By contrast,
activation of peripheral α-adrenergic receptors enhances DA levels in the NAc through effects at
DA terminals. In the present experiment, DOM pretreatment did not alter the effects of ethanol at
DA terminals. However, it did attenuate the increase in NAc DA levels produced by ethanol.
Given these findings, it seems likely that ethanol enhances DA levels in the NAc through a
peripheral D2R-dependent mechanism and not a peripheral α-adrenergic receptor-dependent
mechanism. In the previous study the model posited that IL-10 production and secretion would
be enhanced following activation of peripheral D2Rs. Consistent with this, acute doses of
ethanol have been shown to produce rapid enhancement of IL-10 levels in the hippocampus
(Suryanarayanan et al., 2016), although decreases in IL-10 levels following ethanol
administration have been reported in the amygdala (Marshall et al., 2017). As such, ethanol
enhancement of IL-10 through activation of peripheral D2Rs is a plausible mechanism for the
peripheral D2R mediated effects of ethanol on DA levels in the NAc, although further research is
needed to see if ethanol enhances IL-10 levels in the VTA.
Experiment 2D
Using a backward trace conditioning design (drug US was presented 10 min before the
context CS), it was found that DOM reduced the preference reversal seen following pairing of
the less preferred floor with ethanol or VEH. As this reduction was seen both relative to the
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ethanol group and the VEH group it suggests that antagonism of peripheral D2Rs may be
aversive. As such, the ability of DOM to reduce the preference reversal caused by ethanol may
not reflect involvement of peripheral D2Rs in ethanol reward but rather may reflect aversive
properties of DOM injections. In Experiment 1D the change in preference produced by DOM
administration did not differ from the change in preference produced by VEH administration. In
Experiment 2D DOM administration significantly attenuated the reversal in preference produced
in the VEH control group. There are several key differences between the methodology used in
Experiment 1D and Experiment 2D that could explain why DOM administration did not alter
preference for the DOM paired chamber in Experiment 1 but did so in Experiment 2. First, it is
possible that administration of DOM into the peritoneal cavity is itself aversive. Second, in
Experiment 2D DOM was injected 10 min prior to the subject being placed into the chamber,
and each conditioning session lasted for 20 min rather than 10 min. Finally, in Experiment 2D
subjects received two more trials with DOM than in Experiment 1D. Any of the differences in
these parameters may help to explain the different results in Experiment 1D as compared with
experiment 2D.
Experiment 2E
When combined with low doses of ethanol (0.5 g/kg ip), DOM and ETIC reduced
locomotor activity. However, both drugs enhanced the effects of ethanol at 2.0 g/kg. Once the
direct effects of ETIC on locomotor activity were demonstrated, the binary pattern of effects on
locomotor activity of DOM and ETIC by ethanol were similar. Eticlopride likely attenuated
locomotor activity through its antagonism of central D2Rs (Collins et al., 2010; Schindler &
Carmona, 2002), while also antagonizing peripheral D2Rs, just as DOM does. Domperidone’s
effects when in tandem with ethanol at low doses may be related to the action of the cell
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signaling peptide IL-10.Thus, if DOM decreases ethanol-induced production of IL-10, it may in
turn increase ethanol’s effect on locomotor activity, including sedation.
Conclusion
Ethanol enhanced plasma DA levels in a dose-dependent manner. The injection of DOM
attenuated ethanol enhancement of DA levels in the NAc at doses below 4 g/kg (the dose at
which ethanol enhanced DA neuron firing ex vivo). The sedation-like effects of ethanol on
locomotor activity were modulated by the antagonism of peripheral D2Rs and in a way that
could be interpreted as aversive. Whether they are involved in ethanol’s rewarding effects
remains to be determined.
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Chapter 3
Dopamine receptors fall into two classes, DA subtype-1 (D1)-like receptors (D1Rs) and
D2Rs, based on their pharmacological and structural characteristics, as well as differences in the
modulation of cAMP (Civelli et al., 1993; Kebabian, 1978; Spano et al., 1978). Dopamine
receptors in the brain are expressed throughout the striatum, olfactory tubercle, substantia nigra
(SN), ventral tegmental area (VTA), hypothalamus, cortex, septum, amygdala, pituitary,
thalamus, cerebellum, and hippocampus (Bouthenet et al., 1991; Le Moine & Bloch, 1996). In
the periphery, DA receptors are expressed in the sympathetic ganglia, adrenal glands, heart,
kidneys, blood vessels, gastrointestinal tract, and immune cells (McKenna et al., 2002; Missale et
al., 1998).
Adaptations in D2Rs have been related to AUD. D2R expression is decreased in the
striatum of chronic ethanol consumers (Volkow et al., 1996, 2007). Indeed, high levels of D2R
expression in the striatum may protect against the development of AUD in individuals with a
strong family history of AUD (Volkow et al., 2006). Downregulated striatal D2R expression
(decreased D2R numbers in the striatum) has been shown to recover with prolonged abstinence
from ethanol (Heinz et al., 1996), while the risk of relapse is highest in individuals with
prolonged return to normalized DR2 function (George et al., 1999; Heinz et al., 1996). Finally,
ethanol craving is strongly correlated with decreased striatal D2R expression in humans (Heinz
et al., 2004, 2005), but upregulation of D2R receptors decreases ethanol self-administration in
rats (Thanos et al., 2001).
In addition to the changes in central D2R expression with ethanol use, peripheral D2R
expression is also altered. In chronic drug users, D2R expression in leukocytes varies in a
manner similar to the alterations of D2R expression observed in the brains of chronic drug users
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(Ersche et al., 2011; Goodarzi et al., 2009; Taraskina et al., 2015). This suggests that leukocyte
D2Rs may be a marker for brain D2R expression. Specifically, should this be the case it would
allow for a less invasive and more economical measure of D2R levels than that provided by
positron emission tomography in treatments for AUD.
In this study, I explored peripheral D2R expression as a marker for central D2R
expression. I measured D2R expression in the NAc, medial prefrontal cortex (mPFC), and VTA
at various temporal intervals following an acute dose of ethanol. I also measured D2R expression
in leukocytes following ethanol administration. Finally, I introduced a procedure in which
QUIN, a selective D2R agonist, was pulsed onto VTA GABA neurons over several hours in
order to determine how ethanol affects D2R function and expression in the VTA. I anticipated
that D2R expression on leukocytes would follow D2R expression in the brain at a delay of
approximately 1 hr. This was based on my assumption that D2R-like receptor expression in the
brain would be elevated following an acute dose of ethanol.
Materials and Methods
Animal Subjects
Male Wistar rats weighing more than 250 g from a breeding colony at BYU were used.
Rats were group housed and given ad libitum access to food and water. The housing rooms were
temperature and humidity controlled and lights were maintained on a 12 hr on/12 hr off
light/dark cycle. All experimental procedures were approved by the Institutional Animal Care
and Use Committee at BYU and carried out in accordance with NIH guidelines.
Drugs and Chemicals
Ethanol was diluted to 16% wt/vol in a saline solution of 0.9% sodium chloride.
Dopamine 2 receptor antibodies were obtained from EMD Millipore (Billerica, MA), NeuN
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(neuronal marker) antibodies were obtained from Abcam (Cambridge, MA), Iba-1 (microglial
marker) antibodies were obtained from Wako Chemicals (Richmond, VA), CD45 antibodies
were obtained from Invitrogen (Waltham, MA), and T/B/NK kits were obtained from BD
Biosciences (San Jose, CA). Alexa Fluor secondary antibodies were obtained from Abcam.
Quinpirole hydrochloride was obtained from Tocris Bioscience (Bristol, UK).
Immunohistochemistry for D2Rs, NeuN, and Iba-1
Rats were treated with VEH or ethanol (1.0 g/kg ip) and their brains were removed 30
min, 60 min, or 120 min post-injection. Brains were fixed with 4% formalin, cryoprotected in
30% sucrose, and sectioned into 30 µm sections. Sections from the regions of interest were
incubated with primary antibodies for Iba-1 (1:200), NeuN (1:500), and D2Rs (1:200) and then
with secondary antibodies (1:500). Tissue sections were imaged using a 20x objective on a
Nikon (Tokyo, Japan) Eclipse Ti light microscope. The colocalization of receptors on microglia
and neurons along with fluorescence intensities were obtained using custom scripts written for
ImageJ.
D2R Flow Cytometry
Blood samples were placed in red blood-cell lysis solution for 10 min. The reaction was
stopped by adding phosphate buffered saline, and samples were then centrifuged for 5 min at
2000 rpm. After discarding the supernatant, cells were resuspended in the residual fluid, and cell
staining buffer was added. At this point, the primary antibodies (1:150) and 100 µL of blood
were added to centrifuge tubes. Tubes were then incubated for 15 min, at which point staining
buffer was added to the centrifuge tubes, and samples were gently vortexed followed by
centrifugation at 2000 rpm for 5 min. The supernatant was then discarded, and the secondary
antibodies were added (as necessary). The sample was incubated for 15 min in the secondary
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antibodies, centrifuged, and the supernatant discarded. At this point, cells were filtered, and the
samples were exposed to a fluorescence-activated cell sorting (FACS) procedure on an Attune
Acoustic Focused Flow Cytometer (Applied Biosystems, Waltham, MA).
Single Unit Recordings of GABA Neurons and Quinpirole Iontophoresis
Subjects were anesthetized using isoflurane (1.5% - 2.0%) and placed in a stereotaxic. A
micropipette electrode was inserted into the VTA (from bregma: -5.3 to -5.7 mm AP, +0.6 to
+1.0 mm ML, and -7.8 to -9.2 mm DV) using an Inchworm 8200 microdrive (EXFO Burleigh).
Once a suitable neuron was identified, baseline firing rate was recorded for a minimum of 30
min after which VEH or ethanol (1.0 and 2.0 g/kg ip) was administered, and the firing rate of the
neuron was recorded for an additional 4 hr.
Extracellular potentials were recorded using micropipettes (1 – 4 MΩ) filled with 1.0 M
potassium chloride and QUIN (dissolved 1 mg/ml in potassium chloride). Potentials were
amplified using a Multiclamp 700A amplifier (Molecular Devices, LLC). All other recording
settings and equipment were as described by Ludlow and colleagues, (2009). VTA GABA
neurons were identified using previously established criteria (Steffensen et al., 1998). These
criteria included a relatively fast firing rate (>10 Hz) and an action potential duration of less than
750 µs.
Quinpirole (QUIN) was applied to the GABA neuron by iontophoresis through the
recording electrode using a current-injection method (+30 nA) with the 700A amplifier
(Molecular Devices, LLC). Iontophoresis occurred on a 1-min on/1-min off schedule for the
entire time the neuron was recorded from. The effects of QUIN on the firing rate of the neuron
were calculated by computing the area under the curve (AUC) during the period in which the
neuron was being activated by iontophoresis and then subtracting the (AUC) for the baseline
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firing rate preceding the application of QUIN. These calculations were performed using Igor Pro
(Wavemetrics). The resulting AUC for the period of activation was averaged for three cycles at
the timepoints of interest: baseline (final 3 cycles before ethanol administration) and postadministration at 5 min 15 min, 30 min, 60 min, 120 min, 180 min, and 240 min. Values at each
timepoint were expressed as a percentage of the baseline.
Statistical Analysis
All statistical analyses were performed using Stata 15.1 (StataCorp LLC.) The data were
assessed for outliers using the Shapiro-Wilks test for normality and also the interquartile range
rule. Identified outliers were checked for data-input error. Roughly 4% of the data were
identified as outliers using this method and were replaced with values reflecting the limit used
for outlier detection. Data were analyzed using ANOVAs. A Kruskal-Wallis test was used to
analyze D2R expression data for neurons and microglia, as these data were found to be
distributed non-normally. A Dunn test was used to perform post-hoc comparisons on these data.
The Greenhouse-Geisser correction for sphericity was applied to the results for within-subjects
factors. Post-hoc comparisons were corrected using the Bonferroni correction. All data were
reported are means ± SEM, and all confidence intervals were 95%. For purposes of statistical
analysis, p < 0.05 was considered significant.
Results
Experiment 3A
Average mean fluorescence intensity (MFI) was calculated for D2R expression on
neurons and microglia by averaging the values across all brain slices within a region of interest.
These values were then expressed as a percentage of the mean MFI calculated for the VEHtreated animals in each staining cohort. Dopamine 2 receptor expression on microglia was

PERIPHERAL DOPAMINE RECEPTORS

55

reduced in the mPFC 30 min following ethanol administration (z = -2.80, p = 0.02; see Figure
13B). There were no other significant changes in D2R expression observed on microglia
following ethanol administration. Expression was enhanced on neurons in the NAc 30 min
following ethanol administration (z = -2.52, p = 0.04; see Figure 13C) and 2 hr after ethanol
administration in the mPFC (z = -3.14, p = 0.01). No further changes were observed in D2R
expression.
Figure 13
Ethanol and D2R Expression
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Note. Means are means ± SEM. (A) Representative images of neurons (NeuN), D2Rs, and microglia (Iba1). (B) Dopamine 2 receptor expression on microglia in the mPFC, NAc, and VTA following ethanol (1
g/kg ip) administration. (C) Dopamine 2 receptor expression on neurons in the same three brain regions
following ethanol (1 g/kg ip) administration.

Experiment 3B

PERIPHERAL DOPAMINE RECEPTORS

56

Rats were injected with VEH (n = 18) or ethanol (1 g/kg ip; n = 18), and blood was
drawn 30 min, 1 hr, and 2 hr following the injection. Blood was only drawn once from each rat,
resulting in blood samples from six rats in each treatment condition and temporal interval
combination. Data were the percentage of the average MFI of the VEH treated group at 30 min
post-injection. Ethanol significantly enhanced the expression of D2Rs on B cells (F(1, 30) = 23.78,
p < 0.01, partial η2 = 0.44, CI [0.17, 0.62]; see Figure 14A) and Natural Killer (NK) cells (F(1, 30)
= 9.29, p < 0.01, partial η2 = 0.24, CI [0.03, 0.45]; see Figure 14B) but not in monocytes
(ethanol: F(1, 30) = 1.21, p = 0.28; see Figure 14C) or T cells (ethanol: F(1, 30) = 2.17, p < 0.15; see
Figure 14D). Moreover, the effects were not time dependent.
Figure 14
Ethanol and D2R Expression on Leukocytes
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Note. Data are means ± SEM. (A) The effects on D2R expression of ethanol (1.0 g/kg ip) and VEH in B
cells. (B) In NK cells. (C) In monocytes. (D) In T cells.

Experiment 3C
To further characterize the effects of ethanol on D2R expression and function in the
VTA, I administered VEH (n = 18) or ethanol (1 g/kg ip; n = 17) and applied QUIN via
iontophoresis to GABA neurons during extracellular recordings of firing rate. Researchers had
previously demonstrated that GABA neurons are activated by iontophoresis of DA and that this
activation is D2R dependent (Ludlow et al., 2009). The D2Rs in the VEH-treated group were
desensitized over the course of 4.5 hr, but those in the ethanol-treated group were not (F(1, 33) =
4.74, p = 0.04, partial η2 = 0.13, CI [0.00, 0.33]; ethanol x time: F(7, 221) = 3.01, p = 0.02, partial
η2 = 0.09, CI [0.01, 0.14]; see Figure 15B).
Figure 15
Ethanol’s Effects on D2R Mediated Activation of VTA GABA Neurons Over Time
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Note. Data are means ± SEM. (A) Representative trace of VTA GABA neuron firing rate. The dots at 80
Hz indicate points at which QUIN was applied to the neuron by iontophoresis. (B) Effects of ethanol (1
g/kg ip) and VEH on D2Rs in the VTA GABA neurons following QUIN administration.

Discussion
Dopamine 2 receptor expression on microglia in the mPFC decreased following ethanol
(1 g/kg ip) injection, but D2R expression on neurons in the mPFC and NAc was increased.
Dopamine 2 receptor expression on B and NK cells was enhanced by ethanol. In the VTA, D2Rs
were resistant to desensitization following alcohol injection.
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Experiment 3A
Increased D2R expression on neurons in the NAc and the mPFC following an acute dose
of ethanol supported the hypothesis that D2R expression on neurons parallels central DA levels.
and contradicts the hypotheses that (a) increased DA levels cause downregulation of central
D2Rs (Bartlett et al., 2005; Ghisi et al., 2009; Jones et al., 1999), and that downregulation of
D2Rs in addicted individuals may be unrelated to changes in DA neurotransmission (Wiers et al.,
2016). Further, ethanol does not enhance DA levels in the mPFC (Engleman et al., 2006)
countering the assertion that upregulated D2R levels in the mPFC reflect increased DA release. I
propose an alternative account in which D2R levels are elevated due to the reduced D2R
desensitization resulting from ethanol administration. Under this hypothesis, decreased
internalization (uptake into the cell from the membrane) and degradation (breakdown) of D2Rs
following ethanol administration could lead to ethanol enhanced D2R expression in the NAc and
mPFC.
Experiment 3B
Consistent with previous findings that increased DA levels enhanced D2R expression on
lymphocytes but not on monocytes in vitro (Mitchell et al., 2018), current findings demonstrated
that ethanol enhances D2R expression on NK and B cells (subpopulations of lymphocytes) but
not on monocytes. That D2R expression on NK and B cells is enhanced following an acute dose
of ethanol is plausibly explained by the effects of ethanol on sympathetic tone. However, D2R
expression in T cells (another subset of lymphocytes) did not increase following an acute dose of
ethanol.
Experiment 3C
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The activation of GABA neurons by iontophoresis of QUIN decreased over time in the
VEH-treated group, but a similar decrease was not observed in the ethanol-treated group. This
finding can be interpreted as evidence for the decreased desensitization of D2Rs following an
acute dose of ethanol. Chronic ethanol has previously been shown to decrease the desensitization
of D2Rs in response to QUIN (Perra et al., 2011), although this effect has not been shown with
acute ethanol. It is important to note that, in the current study, GABA neurons, not DA neurons
in the VTA were recorded from. Typically, D2Rs are expressed at much lower levels on GABA
neurons than on DA neurons (Steffensen et al., 2008). Further, D2Rs are typically inhibitory,
although, on rare occasions, cortical D2Rs are known to produce excitation (Robinson & Sohal,
2017). The mechanism whereby activation of D2Rs produces the disinhibition of VTA GABA
neurons is presently unknown. The current data demonstrated reduced desensitization of D2Rs in
the VTA following an acute dose of ethanol.
Conclusion
Acute ethanol increases D2R expression on neurons, NK, and B cells, while decreasing
D2R expression on microglia. These differential effects may reflect both the upregulation of
D2Rs on leukocytes as a result of increased sympathetic tone and the increased expression of
D2Rs on neurons in response to decreased internalization and degradation. Further, decreased
desensitization of D2Rs was demonstrated in VTA GABA neurons following an acute dose of
ethanol. These findings are relevant to the transition from an ethanol-independent to an ethanoldependent condition. Additionally, they indicate that D2R expression on B and NK cells may be
a useful gauge of D2R expression in the brain.
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General Discussion
The three series of experiments in this manuscript examined a pathway involving
peripheral D2Rs that can potentially modulate DA levels in the NAc that have been linked to
rewarding effects. A neuroimmune mechanism was postulated to underlie the function of the
peripheral D2R pathway. Finally, a study of the effects of acute ethanol administration on D2R
expression and function demonstrated that both neuronal D2R expression and D2R expression on
B and NK cells was enhanced. I suggested that these results could be due to both acute ethanol’s
reduction of D2R internalization and degradation and to increased plasma DA levels associated
with increased D2R expression on leukocytes. The findings highlighted similarities in and the
interplay between central DA and peripheral DA functions and their relevance to the genesis of
AUD.
For the study outlined in Chapter 2 the hypotheses were as follow: First, peripheral D2Rs
mediate the ability of IV DA to enhance DA release in the NAc; Second, IV DA will enhance the
firing rate of VTA DA neurons; Third, IV DA will be reinforcing; Fourth, IV DA will enhance
locomotor activity. The first through the third hypotheses were supported by the findings in
Chapter 2 however the fourth hypothesis was not supported.
For the study outlined in Chapter 3 the hypotheses were as follow: First, ethanol will
enhance plasma DA levels; Second, peripheral D2Rs will mediate enhancement of DA levels in
the NAc following ethanol administration; Third, ethanol effects on evoked DA release in the
NAc will not involve D2Rs; Fourth, antagonism of peripheral D2Rs will attenuate reductions in
locomotor activity following ethanol administration. The first through the third hypotheses were
supported by the findings in Chapter 3 but the fourth hypothesis was only partially supported.
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For the study outlined in Chapter 4 the hypotheses were as follow: First, ethanol will
transiently increase D2R expression on neurons; Second, ethanol will increase D2R expression
on circulating leukocytes; Third, ethanol will reduce D2R desensitization. All three hypotheses
were supported by the findings in Chapter 4.
Based on the findings of the studies outlined in Chapters 2-4 I propose several updates to
the model discussed in the introduction to this dissertation (see Figure 16). I propose in response
to acute ethanol administration and activation of D2Rs by increased plasma DA T cells cross the
BBB and release IL-10. I also propose that monocytes increase production of IL-1β in response
to activation of α-adrenergic receptors resulting in increased transport of IL-1β across the BBB.
In response to increased levels of both IL-1β and IL-10 in the VTA DA neurons become
inhibited and DA release in the NAc is increased. These effects could help explain the difference
between the dose of ethanol required to enhance DA neuron firing rate in the VTA in vivo and
that required ex vivo.
Figure 16
Ethanol Effects on the Mesolimbic Pathway
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Note. In the updated model lymphocytes secreting IL-10 cross the BBB following ethanol consumption
while monocytes secrete IL-1β in response to ethanol consumption. The IL-1β secreted by monocytes
outside the brain is then transported across the BBB and into the brain.

Over the course of the studies carried out here at BYU several challenges were
encountered which may affect the interpretability of these results. For example, the behavior
room where rat behavior was carried out was also used as a surgery suite for the first three years
of my time at BYU. This led to numerous disturbances during conditioning and testing as
students entered the room to retrieve items and then left the room. Additionally, the scents in the
room were undoubtedly different depending on the day based on the temporal proximity to the
last time that surgeries were carried out. Finally, the use of fox urine to induce stress in a
posttraumatic stress disorder model within this and other rooms in the vivarium also likely
resulted in variable conditioning and test day performance. These confounds would have all been
present in the behavioral experiments outlined in Chapter 2. The experiments outlined in Chapter
1 were not exposed to these confounds as by the time that they were carried out the behavior
room was separate from the surgical suite and there were no longer other researchers using fox
urine in various rooms in the vivarium. Additionally, additional environmental controls had been
introduced to help isolate the smells in each room from one another and more rapidly turnover
the air in each room.
Another challenge confronted in the course of these experiments was the number of doses
of ethanol administered in each rat in the locomotor activity study (Experiment 2E) in Chapter 2.
In this experiment each rat received 16 doses of ethanol. Although doses were separated by a
minimum of 2 days it is very believable that adaptations may have started to develop in response
to the repeated doses of ethanol. While the order of treatment conditions and ethanol doses were
counterbalanced as best as possible across subjects the large number of injections (20 total)
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relative to the number of subjects (18) may not have allowed counterbalancing to effectively
control for these effects.
Overall I feel that I have been given many opportunities to develop as a researcher and
scholar and while there were challenges they have helped me to grow as an individual. The
facilities at BYU for animal research have been improved by the remodel of the KMBL tower
vivarium although the length and timing of the remodel was detrimental to graduating.
Additionally, differences between the two facilities represent a potential confound in the results
as well although there is not an obvious visual difference in data between that collected in the
LSB and that collected in the KMBL tower.
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